We have located links that may give you full text access.
English Abstract
Journal Article
[Clinical research progress of gene therapy for Leber hereditary optic neuropathy].
[Zhonghua Yan Ke za Zhi] Chinese Journal of Ophthalmology 2018 August 12
Leber hereditary optic neuropathy (LHON) is a mitochondria hereditary eye disease that involves with retinal ganglion cells (RGCs) resulting eventually in degeneration and atrophy of optic nerve. The three mitochondrial DNA mutations (ND4 G11778A, ND1G3460A, ND6T14484C) have been recognized as the primary mutation locus of LHON. Currently there is no effective therapy for LHON. The result of a clinical trial launched in 2007 indicated that intraocular injection of the recombination of adeno-associated virus and target gene is an effective and safe cure for Leber's Congenital Amaurosis (LCA), which brings hope of treating other hereditary eye diseases with gene therapy. Since LHON mainly involves with RGCs, the target gene can be delivered directly to RGCs with the means of injecting the recombination into vitreous cavity, therefore resulting in less damage to retina as compared to other gene therapy for LCA which require the drug to be injected under the retina. This article summarizes the research progress of the clinical trial relevant to gene therapy for LHON. (Chin J Ophthalmol, 2018, 54: 636-640) .
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app